Biogen to Acquire Apellis for $5.6 billion, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease
On Mar. 31, 2026, Biogen and Apellis Pharmaceuticals announced the companies have entered into a definitive agreement under…
-
-
Lilly to acquire Centessa Pharma to advance treatments for sleep-wake disorders in deal worth up to $7.8 Billion
On Mar. 31, 2026, Eli Lilly and Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines…
-
Artificial Intelligence | Biotechnology | Diagnostics | Infectious Disease | Medical Device | Neurology | Pharmaceutical | Therapeutics
China biotech deals hit record as innovative drugs draw interest of multinationals
On Mar. 29, 2026, The South China Morning Post reported the cross-border outlicensing activities of Chinese biotech firms…
-
Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly
On Mar. 29, 2026, generative-AI drug developer Insilico Medicine announced that it has agreed to a global licensing…
-
Biotechnology | Disease | FDA | Pharmaceutical | Rare Disease | Stem Cell
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
On Mar. 27, 2026, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration(FDA) has granted accelerated approval…
-
Biotechnology | Disease | Neurology | Oncology | Pharmaceutical | Quantum
Merck to Acquire Terns Pharmaceuticals for $5.7 Billion, Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia
On Mar. 25, 2026, Merck, and Terns Pharmaceuticals, a clinical-stage oncology company, announced that the companies have entered…
-
UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing Facility
On Mar. 24, 2026, Governor Brian P. Kemp announced that global biopharmaceutical giant UCB, is planning a significant…
-
NIH-awarded life scientist Shu Xiaokun abruptly shifts research from US to China
On Mar. 20, 2026, the South China Morning Post reported that celebrated scientist Shu Xiaokun, Ph.D. leaves prestigious…
-
Agriculture | Artificial Intelligence | Biotechnology | Diagnostics | Environmental | FDA | Genomics | Imaging | Infectious Disease | Medical Device | Medicine | Nanotechnology | Neurology | NIH | Non-Profit Research | Oncology | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine | Veterinary | Women's Health
National survey of NIH-funded researchers shows precarious state of U.S. science — ‘This is like the Titanic’
On Mar. 19, 2026, a nationwide STAT survey of federally funded researchers reveals that, a year after Donald…
-
GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk
On Mar. 13, 2026, GSK announced that the US Food and Drug Administration (FDA) has expanded the approved…
-
Tomatoes, carrots, and lettuce store pharmaceutical byproducts in their leaves
On Mar. 12, 2026, Johns Hopkins University (JHU) researchers release study findings that suggest that some vegetables may…
-
Biotechnology | Diagnostics | Medical Device | Medicine | Neurology | Non-Profit Research | Oncology | Pharmaceutical | Radiology | Therapeutics
Mass General Brigham Receives Transformative $50 Million Gift to Shape Future of Cancer Research
On Mar. 12, 2026, Mass General Brigham (MGB) announced it has received a $50 million gift that will…
-
Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Ireland
On Mar. 2, 2026, Novo Nordisk announced an investment of 432 million euro (approx. DKK 3.2 billion) in…
-
Novartis settles with Henrietta Lacks’ estate over use of her ‘stolen’ cells to advance medicine
On Feb. 26, 2026, Novartis announced it has settled a lawsuit by the estate of Henrietta Lacks that…
-
Merck and Mayo Clinic Announce R&D Collaboration Supporting AI-Enabled Drug Discovery and Precision Medicine
On Feb. 18, 2026, Merck, known as MSD outside of the U.S. and Canada, and Mayo Clinic, the…
-
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
On Feb. 18, 2026, Johnson & Johnson announced announced a more than $1 billion investment in a next…
-
Artificial Intelligence | Biotechnology | Genomics | Materials | Medical Device | Nanotechnology | Non-Profit Research | Pharmaceutical | Quantum | Therapeutics | U.S. Congress
PNNL Powers Biotechnology, Grid Operations, Nuclear Science Through Genesis AI for Science Mission
On Feb. 17, 2026, the Department of Energy’s (DOE) Pacific Northwest National Laboratory (PNNL) announces it has joined…
-
Lilly to acquire Orna Therapeutics to advance cell therapies for $2.4 billion in cash
On Feb. 9, 2026, Eli Lilly and Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in…
-
Lilly selects Pennsylvania for new injectable medicine and device manufacturing facility
On Jan. 30, 2026, Eli Lilly announced plans to invest more than $3.5 billion in a new manufacturing…
-
Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
On Jan. 28, 2026, U.S. drugmaker Eli Lilly announces signing an agreement worth up to $1.12 billion with…
-
Google DeepMind launches AI tool to help identify genetic drivers of disease
On Jan. 28, 2026, researchers at Google DeepMind have unveiled their latest artificial intelligence tool and claimed it…
-
UCLA chemists just broke a 100-year-old rule and say it’s time to rewrite the textbooks
On Jan. 23, 2026, chemists from the University of California, Los Angeles (UCLA) have found a big problem…
-
Biotechnology | Clinical Research | Diagnostics | FDA | Genomics | Infectious Disease | Medical Device | Medicine | Non-Profit Research | Oncology | Ophthalmogy | Organ Transplant | Pharmaceutical | Rare Disease | Therapeutics | U.S. Congress | Vaccine | Women's Health
U.S. healthcare spending soars to over $5 trillion in 2024
On Jan. 14, 2026, U.S. healthcare spending rose by 7.2% to $5.3 trillion in 2024 from $4.9 trillion…
-
AbbVie and U.S. Administration Reach Agreement to Improve Access and Affordability for Americans
On Jan. 12, 2026, AbbVie announced a voluntary agreement with the Trump administration to further advance access and…
-
AbbVie Acquires Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the U.S.
On Jan. 12, 2026, AbbVie and West Pharmaceutical Services announced a definitive agreement for AbbVie to acquire a…
-
Chinese drug makers strike a record US$136 billion in out-licensing deals in 2025
On Jan. 8, 2026, Chinese drug makers’ licensing deals more than doubled in 2025 from a year earlier…
-
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases for $1.2 billion
On Jan. 7, 2025, Eli Lilly and Ventyx Biosciences, a San Diego-based clinical-stage biopharmaceutical company focused on developing…
-
Novartis and U.S. government reach agreement on lowering drug prices
On Dec. 19, 2025, Novartis, a leading global innovative medicines company, announced it has reached an agreement with…
-
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases
On Dec. 19, 2025, BioMarin Pharmaceutical and Amicus Therapeutics announced that BioMarin has entered into a definitive agreement…
-
Adaptive Inks deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases woth $890 Million
On Dec. 15, 2025, Adaptive Biotechnologies announced it has signed two non-exclusive deals with Pfizer to support research…
